Targeting menin for precision therapy in high-risk acute myeloid leukemia

Objective: This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways. Summary: The clinica...

Full description

Bibliographic Details

Published in:	Leukemia Research Reports
Main Authors:	Abdur Jamil, Zaheer Qureshi, Zain Mary El-amir, Gillian Kupakuwana-Suk, Hamzah Akram, Mohsin Ahmad, Eric Huselton
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Subjects:	Acute myeloid leukemia Revumenib KMT2A Menin inhibition therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213048924000852